



**For Immediate Release**

Contact: [patricia@csidryeye.com](mailto:patricia@csidryeye.com)  
[info@csidryeye.com](mailto:info@csidryeye.com)

#130 1016 68th Ave. SW,  
Calgary, AB T2V 4J2

**CSI Dry Eye Innovations Announces Major Brand Evolution and Newly Issued Patent for Its AI-Supported Clinical Decision Support Platform**

**Calgary – January 27, 2026** – CSI Dry Eye Innovations announced the introduction of its new corporate brand alongside the issuance of a patent for its flagship product, CSI Dry Eye Software. Together, these milestones reflect the company's long-term vision and its commitment to advancing dry eye care through clinically rigorous, evidence-based innovation.

The establishment of CSI Dry Eye Innovations formalizes a future-focused brand architecture that serves as the parent brand for current and future offerings. Under this structure, CSI Dry Eye Software remains the company's primary product, protected by the newly issued patent. This evolution reflects CSI's growth into a long-term clinical partner and a holistic digital hub for dry eye care.

As dry eye management becomes increasingly complex, the CSI Dry Eye Innovations brand emphasizes responsibility, trust, and consistency, while signaling continued investment in platform capabilities designed to support clinicians, standardize care delivery, and improve patient outcomes over time.

"Dry eye is not a single disease. It is a complex, multifactorial condition that requires thoughtful clinical reasoning," said Dr. Ahmed Al-Ghoul, MD, Founder of CSI Dry Eye Innovations. "This patent recognizes the importance of structured, explainable decision support, not automation, in helping clinicians deliver consistent, high-quality dry eye care".

**A Groundbreaking Patent for Dry Eye Care**

The newly issued patent protects the core clinical reasoning framework behind CSI Dry Eye Software. Unlike tools that rely on isolated test results or basic data capture, the patented process analyzes multiple dry eye indicators, determines sub-type and severity, and generates explainable, ranked treatment pathways to support clinical decision-making. The software does not diagnose autonomously or replace clinician judgment. Instead, it provides standardized, evidence-based structure while preserving full clinical authority.

## **A Brand Built for the Future of Dry Eye Care**

The launch of CSI Dry Eye Innovations includes a refreshed visual identity, a new website coming, and clearer communication of CSI's role in dry eye care. This evolution reflects a commitment to responsible AI, clinically grounded innovation, and tools that continue to learn and improve alongside clinicians.

"At its core, this brand represents where CSI is headed," said Lisa Rickards, CEO of CSI Dry Eye Innovations. "Dry eye is a rapidly evolving and increasingly complex condition, and our focus is on building intuitive, clinically structured tools that help clinicians deliver consistent, efficient, and confident care."

[CSI Dry Eye Innovations](#) is a software company dedicated to supporting eye care professionals through AI-supported clinical decision tools, led by its flagship product, CSI Dry Eye Software.